Compare AST SpaceMobile Inc (ASTS) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AST SpaceMobile Inc vs Medpace Holdings Inc — how do they compare? AST SpaceMobile Inc trades at $72.3 (market cap $21.90B), while Medpace Holdings Inc trades at $538.23 (market cap $15.37B). The key difference: AST SpaceMobile Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, AST SpaceMobile Inc nearer its low. Which is the better fit depends on your goals.
| ASTS | MEDP | |
|---|---|---|
Market Cap | $21.90B | $15.37B |
Sector | Media | Technology |
52-Week High | $133.09 | $620.59 |
52-Week Low | $36.91 | $308.88 |
Enterprise Value | $21.87B | $14.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASTS trades at $73.32, down 0.76% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported revenue of $70.92 million in 2025 but sustained a net loss of $341.94 million, missing earnings expectations for three consecutive quarters. Recent news highlights potential in defense communications via satellite technology, though competition with SpaceX remains a focal point.
The outlook is speculative with high execution risk; analyst consensus is divided with a $90.33 price target. Investment opportunity hinges on successful satellite deployment and partnership execution, but persistent losses and intense competition pose significant downside risks for shareholders.
MEDP trades at $538.23, up 0.51% with a bullish technical signal and strong fundamentals. The stock shows robust profitability with 17.19% net margins and 77.25% ROE, though valuations appear elevated with a P/E of 33.87. Recent earnings consistently beat expectations, and 2026 projections indicate revenue growth to $2.7B. Technical analysis shows support at $527 and resistance at $543, with the current price near pivot point $535.
MEDP presents growth potential from strong CRO demand and earnings momentum, but faces risks from class action lawsuits and elevated valuation multiples. Analyst consensus is cautious with 74% hold ratings and a $479 price target below current levels. The stock's outlook depends on maintaining backlog quality amid rising cancellations and AI investment delays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
